Research presentation

Digital Health Innovation in Cardiovascular Diseases (Executive Briefing)

Read these Executive Briefing extracts from the Digital Health in Cardiovascular Diseases (Premium) report, exclusively available to HealthTech Alpha Pro and HealthTech Alpha Enterprise users. Sign up on HealthTech Alpha to get your copy.

Request the presentation Discuss the findings

Cardiovascular Diseases Thematic Report

Digital Health Innovation in Cardiovascular Diseases is experiencing a surge of interest as evidenced by the recent significant increase in partnerships in 2023 compared to the same quarter in 2022.

Among the ventures with solutions for Clinical Trials, they are leading in clinical evidence with over half of them having an Evidence Signal greater than 40. This is a promising sign for the future of Cardiovascular Disease treatment as it suggests that these ventures are producing effective solutions that are backed by strong clinical evidence.

However, the total venture capital funding for Cardiovascular solutions in Digital Health decreased by 31% from 2021 to 2022, totaling $3.4B in 2022. This could be due to a number of factors such as market conditions or investor sentiment.

Additionally, the exit activity for Cardiovascular ventures was low in 2022 which followed on in the first quarter of 2023. This could indicate that investors are taking a more cautious approach towards Cardiovascular ventures, or that there are simply fewer opportunities for acquisition.

It’s worth noting that from 2020 to 2023, Patient Solutions was one of the top 3 largest clusters for newly incorporated ventures that focused primarily on Cardiovascular Diseases. This suggests that there is a growing focus on patient-centered solutions in this area of healthcare, which could lead to more effective and personalized treatments for patients with Cardiovascular Diseases.

The “Digital Health Innovation in Cardiovascular Diseases” report includes data on the following companies: Withings, LifeSignals, Eko, Huinno, Omada, Viz.ai, US2.AI, Cleerly, Recora, Elfie, AstraZeneca, Novartis, Roche, Johnson & Johnson, Janssen, Viatris, Servier, Sanofi, Medtronic, Abbott, Boston Scientific, Edwards Lifesciences, SOPHiA Genetics, Integrity Healthcare, Jana Care, One Drop, Tempus, Biofourmis, DispatchHealth, BioIntelliSense, Owkin, Athelas, Koneksa Health, Volta Medical, Implicity, HaploX, CureApp, GOQii, Cathworks, Hello Heart, Cardiokol, Caption Health, Biim Ultrasound, NeuTrace, Arterys, Nutrimedy, Profusa, Foxo Technologies, Novant Health, Mayo Clinic, Rohto Pharmaceutical, Augusta University Health, Franciscan Missionaries of Our Lady Health Systems, GE Healthcare, Observe Medical, Anumana, FemTec Health, TytoCare, Ultromics, FiNC Technologies, Gather Health, Examedi, Medical Informatics, Lark Health, Khosla Ventures, General Catalyst, Bpifrance, DCVC, Asset Management Ventures

This is the executive briefing of the Digital Health in Cardiovascular Diseases (Premium) report which is exclusively available to HealthTech Alpha Pro and HealthTech Alpha Enterprise users.

HealthTech Alpha, a Galen Growth proprietary solution, powers this report!

How to Cite This Report

APA: Galen Growth. (2023). Digital Health Innovation in Cardiovascular Diseases (Executive Briefing). HealthTech Alpha. https://www.galengrowth.com/product/digital-health-in-cardiovascular-diseases-headlines/

Short form: Galen Growth / HealthTech Alpha, 2023.

Transform research into action

Build an Alpha Brief from the Cardiovascular Diseases research

Alpha Briefs turn Galen Growth research into a focused commercial intelligence brief tailored to a strategic objective. Use the builder to classify the commercial pathway, select the right delivery product, and describe the business outcome you want to enable.

What Alpha Briefs are

Focused intelligence briefs that translate research evidence into market awareness, account expansion, or sponsored thought leadership opportunities.

What they are not

Generic report downloads. Each brief is scoped around a commercial pathway, audience signal, and next-step use case.

1. Which commercial pathway should this brief support?

2. What delivery product should Galen Growth shape from this research?

3. What outcome should the Alpha Brief make easier?

4. Add useful context, constraints, or target audience. (Optional)

Alpha Brief

Generated outline

Choose a pathway, product, and outcome. We will turn it into a commercial intelligence brief request.

Complete the first three prompts to add your contact details. The fourth prompt is optional but helps us scope the brief faster.

Next step

Want the analysis behind the slides?

Tell us what decision you are trying to make. We can shape the data, company universe, and strategic interpretation around your market, portfolio, partnership, or investment question.

Engage Galen Growth

Digital Health Innovation in Cardiovascular Diseases (Executive Briefing)

Build an Alpha Brief from the Cardiovascular Diseases research

Want the analysis behind the slides?

Overview

Category

Stage

Total Funding

GGA Score